<DOC>
	<DOCNO>NCT02807987</DOCNO>
	<brief_summary>To examine antihypertensive effect safety administration CS-3150 combination ARB ACE inhibitor hypertensive patient moderate renal impairment .</brief_summary>
	<brief_title>Study CS-3150 Combination With ARB ACE Inhibitor Hypertensive Patients With Moderate Renal Impairment</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Mineralocorticoid Receptor Antagonists</mesh_term>
	<mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
	<criteria>Male female subject age 20 order 80 young year inform consent Subjects hypertension ( Sitting SBP ≥ 140 mmHg , &lt; 180 mmHg Sitting DBP ≥ 80 mmHg , &lt; 110 mmHg Treatment ARB ACE inhibitor eGFR ≥ 30 mL/min/1.73 m2 &lt; 60 mL/min/1.73 m2 Secondary hypertension malignant hypertension Diabetes mellitus albuminuria Subjects Insulin treatment Subjects preplanned hemodialysis Serum potassium level &lt; 3.5 ≥ 4.8 mEq/L</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Mineralocorticoid receptor antagonist</keyword>
	<keyword>Moderate renal impairment</keyword>
	<keyword>Hypertension</keyword>
</DOC>